Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 236-240

  Sengsayadeth, S ^a   Savani, B N ^a   Jagasia, M ^a   Goodman, S ^a   Greer, J P ^a   Chen, H ^b   Chinratanalab, W ^a   Kassim, A A ^a   Engelhardt, B G ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Acute GVHD; Clinical trials; Hematopoietic cell transplant

Indexed keywords

ACUTE DISEASE; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84893731028     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.157     Document Type: Article

References (10)

1. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C et al. First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the american society of blood and marrow transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-1163.
2. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115: 5412-5417.
3. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA et al. Novel treatment concepts for graft-versus-host disease. Blood 2012; 119: 16-25.
4. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012; 47: 125-131.
5. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J et al. Graft-versushost disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010; 16: 1693-1699.
6. Martin PJ. Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 357-372.
7. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P et al. Tissue-specific regulatory T cells; biomarker for acute graft-versus-host disease and survival. Exp Hematol 2012; 40: 974-982.
8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
9. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
10. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant 2009; 15: 777-784.